DB:KK3A

Stock Analysis Report

Executive Summary

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.


Snowflake Analysis

Imperfect balance sheet with concerning outlook.


Similar Companies

Share Price & News

How has Cytokinetics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KK3A's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.7%

KK3A

-4.1%

DE Biotechs

-5.7%

DE Market


1 Year Return

116.2%

KK3A

3.7%

DE Biotechs

6.1%

DE Market

Return vs Industry: KK3A exceeded the German Biotechs industry which returned 5.5% over the past year.

Return vs Market: KK3A exceeded the German Market which returned 8.3% over the past year.


Shareholder returns

KK3AIndustryMarket
7 Day0.7%-4.1%-5.7%
30 Day19.3%-8.2%-5.7%
90 Day60.9%-2.0%-3.6%
1 Year116.2%116.2%4.0%3.7%9.3%6.1%
3 Year43.7%43.7%38.2%36.7%8.9%-0.7%
5 Year94.3%94.3%9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is Cytokinetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cytokinetics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Cytokinetics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cytokinetics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Cytokinetics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-10.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KK3A is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KK3A is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KK3A is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KK3A's revenue (6.9% per year) is forecast to grow faster than the German market (5.1% per year).

High Growth Revenue: KK3A's revenue (6.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if KK3A's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Cytokinetics performed over the past 5 years?

-43.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KK3A is currently unprofitable.

Growing Profit Margin: KK3A is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: KK3A is unprofitable, and losses have increased over the past 5 years at a rate of -43.9% per year.

Accelerating Growth: Unable to compare KK3A's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KK3A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: KK3A's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Cytokinetics's financial position?


Financial Position Analysis

Short Term Liabilities: KK3A has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: KK3A has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: KK3A has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: KK3A's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: KK3A has a low level of unsold assets or inventory.

Debt Coverage by Assets: KK3A has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KK3A has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: KK3A has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -34.2% each year.


Next Steps

Dividend

What is Cytokinetics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate KK3A's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate KK3A's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KK3A's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KK3A's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KK3A's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.4yrs

Average management tenure


CEO

Robert Blum (55yo)

13.1yrs

Tenure

US$3,265,575

Compensation

Mr. Robert I. Blum has been President and Chief Executive Officer of Cytokinetics, Incorporated since January 22, 2007. Mr. Blum previously served as President from February 2006 to January 2007, Executive ...


CEO Compensation Analysis

Compensation vs Market: Robert's total compensation ($USD3.27M) is above average for companies of similar size in the German market ($USD1.31M).

Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Robert Blum
CEO, President & Director13.1yrsUS$3.27m0.061% $510.6k
Ching Jaw
Senior VP & CFO2.7yrsUS$953.95k0.085% $703.9k
David Cragg
Chief Human Resources & Administration Officer1.1yrsUS$980.00k0.13% $1.1m
Fady Malik
Executive Vice President of Research & Development7.7yrsUS$1.53m0.070% $582.1k
James Spudich
Co-Founder & Member of Scientific Advisory Board0yrsUS$21.94kno data
Robert Wong
VP & Chief Accounting Officer0.8yrsno datano data
Diane Weiser
Vice President of Investor Relations & Corporate Communications4.8yrsno datano data
Bonnie Charpentier
Senior Vice President of Regulatory Affairs & Compliance6.1yrsUS$1.06mno data
Mark Schlossberg
Senior VP of Legal & General Counsel1.1yrsno datano data
Andrew Wolff
Senior VP15.4yrsUS$728.15kno data

5.4yrs

Average Tenure

58yo

Average Age

Experienced Management: KK3A's management team is seasoned and experienced (5.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Blum
CEO, President & Director13.1yrsUS$3.27m0.061% $510.6k
James Spudich
Co-Founder & Member of Scientific Advisory Board0yrsUS$21.94kno data
B. Parshall
Independent Director7yrsUS$207.24kno data
Santo Costa
Independent Director9.3yrsUS$188.31kno data
James H. Sabry
Co-Founder & Chairman of Scientific Advisory Board11.8yrsUS$41.50kno data
Ronald Vale
Member of Scientific Advisory Board0yrsno datano data
Thomas Pollard
Member of Scientific Advisory Board0yrsno datano data
David Morgans
Member of Scientific Advisory Board3.6yrsUS$942.23kno data
Lawrence Goldstein
Member of Scientific Advisory Board0yrsno datano data
Leonard Gage
Chairman9.9yrsUS$280.55k0.054% $448.4k

9.6yrs

Average Tenure

66yo

Average Age

Experienced Board: KK3A's board of directors are considered experienced (9.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.


Top Shareholders

Company Information

Cytokinetics, Incorporated's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cytokinetics, Incorporated
  • Ticker: KK3A
  • Exchange: DB
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$903.981m
  • Listing Market Cap: US$832.837m
  • Shares outstanding: 59.16m
  • Website: https://www.cytokinetics.com

Number of Employees


Location

  • Cytokinetics, Incorporated
  • 280 East Grand Avenue
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CYTKNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDApr 2004
KK3ADB (Deutsche Boerse AG)YesCommon StockDEEURApr 2004

Biography

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase I clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 21:17
End of Day Share Price2020/02/24 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.